Taisho Files Domestic Application In Japan For SGLT2 Inhibitor Luseogliflozin
This article was originally published in PharmAsia News
Executive Summary
Taisho Pharmaceutical Holdings filed a domestic application for the approval of new hypoglycemic agent TS-071 (luseogliflozin) April 18.